Cocaine, benzoylecgonine, amphetamine, and N-acetylamphetamine binding to melanin subtypes

Journal of Analytical Toxicology

Volumn 27, Issue 3, 2003, Pages 125-134

  Borges, Chad R ^a,b   Roberts, Jeanette C ^a   Wilkins, Diana G ^a   Rollins, Douglas E ^a  

^a UNIVERSITY OF UTAH   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDROXYINDOLE; 5,6 DIHYDROXYINDOLE 2 CARBOXYLIC ACID; AMPHETAMINE; BENZOYLECGONINE; CATECHOL; COCAINE; EUMELANIN; MELANIN; N ACETYLAMPHETAMINE; PHEOMELANIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG BINDING SITE; DRUG DETERMINATION; DRUG HAIR LEVEL; HAIR; HAIR ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 12444315623     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/27.3.125     Document Type: Article

References (47)

1. B. Larsson and H. Tjalve. Studies on the mechanism of drugbinding to melanin. Biochem. Pharmacol. 28: 1181-1187 (1979).
2. K.B. Stepien and T. Wilczok. Studies of the mechanism of chloroquine binding to synthetic DOPA-melanin. Biochem. Pharmacol. 31: 3359-3365 (1982).
3. G. Prota. Melanin-producing cells. In Melanins and Melanogenesis. Academic Press, San Diego, CA, 1992, pp 14-33.
4. A. Limat, D. Salomon, P. Carraux, J.H. Saurat, and T. Hunziker. Human melanocytes grown in epidermal equivalents transfer their melanin to follicular outer root sheath keratinocytes. Arch. Dermatol. Res. 291: 325-332 (1999).
5. N.G. Lindquist. Accumulation of drugs on melanin. Acta Radiol. Diagn. (Stockh.) 325: 1-92 (1973).
6. N.G. Lindquist and S. Ullberg. The melanin affinity of chloroquine and chlorpromazine studied by whole body autoradiography. Acta Pharmacol. Toxicol. (Copenh.) 2: 1-32 (1972).
7. B.S. Larsson. Interaction between chemicals and melanin. Pigment Cell Res. 6: 127-133 (1993).
8. K. Shimada, R. Baweja, T. Sokoloski, and P.N. Patil. Binding characteristics of drugs to synthetic levodopa melanin. J. Pharm. Sci. 65: 1057-1060 (1976).
9. M. Fukuda and K. Sasaki. Changes in the antibacterial activity of melanin-bound drugs. Ophthalmic Res. 22: 123-127 (1990).
10. R.M. Barr-Hamilton, L.M. Matheson, and D.G. Keay. Ototoxicity of cis-platinum and its relationship to eye colour. J. Laryngol. Otol. 105: 7-11 (1991).
11. J.W. Conlee, M.L. Bennett, and D.J. Creel. Differential effects of gentamicin on the distribution of cochlear function in albino and pigmented guinea pigs. Acta Otolaryngol. 115: 367-374 (1995).
12. E. Zemel, A. Loewenstein, B. Lei, M. Lazar, and I. Perlman. Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity. Invest. Ophthalmol. Vis. Sci. 36: 1875-1884 (1995).
13. R.J. D'Amato, Z.P. Lipman, and S.H. Snyder. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231: 987-989 (1986).
14. R.J. D'Amato, G.M. Alexander, R.J. Schwartzman, C.A. Kitt, D.L. Price, and S.H. Snyder. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327: 324-326 (1987).
15. R.J. D'Amato, D.F. Benham, and S.H. Snyder. Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin. J. Neurochem. 48: 653-658 (1987).
16. R.J. D'Amato, G.M. Alexander, R.J. Schwartzman, C.A. Kitt, D.L. Price, and S.H. Snyder. Neuromelanin: a role in MPTP-induced neurotoxicity. Life Sci. 40: 705-712 (1987).
17. E.Y. Wu, K. Chiba, A.J. Trevor, and N. Castagnoli, Jr. Interactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium species with synthetic dopamine-melanin. Life Sci. 39: 1695-1700 (1986).
18. M. d'Ischia and G. Prota. Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update. Pigment Cell Res. 10: 370-376 (1997).
19. G. Prota and M. d'Ischia. Neuromelanin: a key to Parkinson's disease. Pigment Cell Res. 6: 333-335 (1993).
20. D. Ben-Shachar and M.B. Youdim. Iron, melanin and dopamine interaction: relevance to Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 17: 139-150 (1993).
21. S.P. Gygi, R.E. Joseph, Jr., E.J. Cone, D.G. Wilkins, and D.E. Rollins. Incorporation of codeine and metabolites into hair. Role of pigmentation. Drug Metab. Dispos. 24: 495-501 (1996).
22. M.H. Slawson, D.G. Wilkins, and D.E. Rollins. The incorporation of drugs into hair: relationship of hair color and melanin concentration to phencyclidine incorporation. J. Anal. Toxicol. 22: 406-413 (1998).
23. K. Hold, D. Wilkins, D. Crouch, D. Rollins, and R. Maes. Detection of stanozolol in hair by negative ion chemical ionization mass spectrometry. J. Anal. Toxicol. 20: 345-349 (1996).
24. R.E. Joseph, Jr., T.P. Su, and E.J. Cone. In vitro binding studies of drugs to hair: influence of melanin and lipids on cocaine binding to Caucasoid and Africoid hair. J. Anal. Toxicol. 20: 338-344 (1996).
25. T. Mieczkowski and R. Newel. Statistical examination of hair color as a potential biasing factor in hair analysis. Forensic Sci. Int. 107: 13-38 (2000).
26. C.K. Kelly, T. Mieczkowski, S.A. Sweeney, and J.A. Bourland. Hair analysis for drugs of abuse. Hair color and race differentials or systematic differences in drug preferences? Forensic Sci. Int. 107: 63-86 (2000).
27. S.P. Gygi, D.G. Wilkins, and D.E. Rollins. A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. J. Pharm. Sci. 86: 209-214 (1997).
28. C.R. Borges, D.G. Wilkins, and D.E. Rollins. Amphetamine and N-acetylamphetamine incorporation into hair: an investigation of the potential role of drug basicity in hair color bias. J. Anal. Toxicol. 25: 221-227 (2001).
29. L. Novellino, A. Napolitano, and G. Prota. Isolation and characterization of mammalian eumelanins from hair and irides. Biochim. Biophys. Acta 1475: 295-306 (2000).
30. D.L. Hubbard, D.G. Wilkins, and D.E. Rollins. The incorporation of cocaine and metabolites into hair: effects of dose and hair pigmentation. Drug Metab. Dispos. 28: 1464-1469 (2000).
31. K. Wakamatsu and S. Ito. Preparation of eumelanin-related metabolites 5,6-dihydroxyindole, 5,6-dihyroxyindole-2-carboxylic acid, and their O-methyl derivatives. Anal. Biochem. 170: 335-340 (1988).
32. S. Ito, K. Wakamatsu, and H. Ozeki. Spectrophotometric assay of eumelanin in tissue samples. Anal. Biochem. 215: 273-277 (1993).
33. S. Ito, S. Inoue, Y. Yamamoto, and K. Fujite. Synthesis and antitumor activity of cysteinyl-3,4-dihydroxyphenylalanines and related compounds. J. Med. Chem. 24: 673-677 (1981).
34. S. Ito and K. Fujita. Microanalysis of eumelanin and pheomelanin in hair and melanomas by chemical degradation and liquid chromatography. Anal. Biochem. 144: 527-536 (1985).
35. C.R. Borges, J.C. Roberts, D.G. Wilkins, and D.E. Rollins. Relationship of melanin degradation products to actual melanin content: application to human hair. Anal. Biochem. 290: 116-125 (2001).
36. J. Halmekoski and P. Saarinen. Synthesis of acetyl derivatives of some sympathomimetic amines. Farmaseuttinen Aikakauslehti 75: 335-353 (1966).
37. H. Ibrahim and A.F. Aubry. Development of a melanin-based highperformance liquid chromatography stationary phase and its use in the study of drug-melanin binding interactions. Anal. Biochem. 229: 272-277 (1995).
38. A.N. Martin, J. Swarbrick, and A. Camarata. Physical Pharmacy, Lea & Febiger, Philadelphia, PA, 1969, p 434.
39. R. Baweja, T.D. Sokoloski, and P.N. Patil. Competitive binding between cocaine and various drugs to synthetic levodopa melanin. J. Pharm. Sci. 66: 1544-1547 (1977).
40. C.C. Felix, J.S. Hyde, T. Sarna, and R.C. Sealy. Interactions of melanin with metal ions: Electron spin resonance evidence for chelate complexes of metal ions with free radicals. J. Am. Chem. Soc. 100: 3922-3926 (1978)
41. A.H. Lowrey, G.R. Famini, V. Loumbev, L.Y. Wilson, and J.M. Tosk. Modeling drug-melanin interaction with theoretical linear solvation energy relationships. Pigment Cell Res. 10: 251-256 (1997).
42. U. Mars and B.S. Larsson. Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res. 12: 266-274 (1999).
43. Y. Nakahara and R. Kikura. Hair analysis for drugs of abuse. XIII. Effect of structural factors on incorporation of drugs into hair: the incorporation rates of amphetamine analogs. Arch. Toxicol. 70: 841-849 (1996).
44. R.E. Joseph, Jr., W.J. Tsai, L.I. Tsao, T.P. Su, and E.J. Cone. In vitro characterization of cocaine binding sites in human hair. J. Pharmacol. Exp. Ther. 282: 1228-1241 (1997).
45. R.E. Joseph, Jr., K.M. Hold, D.G. Wilkins, D.E. Rollins, and E.J. Cone. Drug testing with alternative matrices II. Mechanisms of cocaine and codeine deposition in hair. J. Anal. Toxicol. 23; 396-408 (1999).
46. C.R. Borges, S.D. Martin, L.J. Meyer, D.G. Wilkins, and D.E. Rollins. Influx and efflux of amphetamine and N-acetylamphetamine in keratinocytes, pigmented melanocytes, and nonpigmented melanocytes. J. Pharm. Sci. 91: 1523-1535 (2002).
47. D.E. Rollins, D.G. Wilkins, A. Mizuno, M.H. Slawson, and C.R. Borges. The role of pigmentation in the disposition of drugs of abuse in human hair. Clin. Pharm. Exp. Ther. 67: 113 (2000).